ALIM实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally...

Stats
今日成交量	143 580
平均成交量	71 388.00
市值	191.17M
EPS	$0 ( 2024-03-07 )
下一个收益日期	( $-0.0400 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.35
ATR14	$0.0200 (0.54%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Ashman Philip	Sell	12 103	Common Stock
2024-03-11	Werner Jason M.	Buy	1 800	Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Performance-Based Restricted Stock Units
2024-03-11	Wood Todd Michael	Buy	125 000	Restricted Stock Units
2024-03-11	Eiswirth Richard S Jr	Buy	14 700	Restricted Stock Units

INSIDER POWER
27.03
Last 77 transactions
Buy: 33 555 909 \| Sell: 20 075 544

音量相关性

長: 0.06 (neutral)

短: -0.25 (neutral)

Signal:(41.28) Neutral

Alimera Sciences Inc 相关性

10 最正相关
ADV	0.943
RCMT	0.942
BTWN	0.941
AMZN	0.933
USLM	0.933
KE	0.93
RXST	0.929
HUSN	0.928
MRAM	0.928
ALTO	0.928

10 最负相关
AKU	-0.948
IMBI	-0.942
AMRB	-0.936
RMBS	-0.93
STRM	-0.928
AGRI	-0.927
ENNV	-0.924
LOPE	-0.923
EYEN	-0.921
PTMN	-0.919

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alimera Sciences Inc 相关性 - 货币/商品

-0.85
( strong negative )

-0.87
( strong negative )

0.00
( neutral )

-0.84
( strong negative )

0.13
( neutral )

0.78
( moderate )

Alimera Sciences Inc 财务报表

Annual	2023
营收:	$80.75M
毛利润:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2023
营收:	$80.75M
毛利润:	$61.17M (75.75 %)
EPS:	$-0.790

FY	2022
营收:	$54.13M
毛利润:	$46.15M (85.26 %)
EPS:	$-2.59

FY	2021
营收:	$59.03M
毛利润:	$52.00M (88.09 %)
EPS:	$-0.854

Financial Reports:

No articles found.

Alimera Sciences Inc

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.